Radar on Drug Benefits

Expert: Consumers Need More Info on Complex Drug Benefits

Employer-sponsored plans have “increasingly complex” prescription drug cost-sharing arrangements, according to the Kaiser Family Foundation’s (KFF) 2020 Employer Health Benefits Survey. But one expert says tha...
0 Comments
© 2024 MMIT

News Briefs

✦ HHS and the Dept. of Defense reached a deal with CVS Health Corp. and Walgreen Co. to provide and administer COVID-19 vaccines to residents of long-term care facilities (LTCF) nationwide, with no out-of-pocket c...
0 Comments
© 2024 MMIT

SCOTUS Hearing Hints at PBM Win in Case Against State Regs

Following an Oct. 6 Supreme Court hearing, legal experts tell AIS Health that PBMs appear to have a good shot at prevailing in their challenge of a 2015 Arkansas law, which has major implications for how both health...
0 Comments
© 2024 MMIT

CVS, Optum Exclude Inhalers, Switch Diabetes Supplies for ’21 With Chart: Major PBMs Release 2021 Formulary Exclusions

Editor's Note: A previous version of this article misstated how OptumRx is covering Tecfidera, Ruxience, Rituxan and Truxima. This version has been corrected. CVS Health Corp.’s Caremark will exclude 57 medicat...
0 Comments
© 2024 MMIT

UnitedHealth Reportedly Moves to Buy PillPack Competitor

More than two years after Amazon Inc. unveiled its plan to acquire PillPack, which specializes in pre-sorted dose packaging and home delivery of prescription drugs (RDB 7/13/18, p. 1), UnitedHealth Group has reporte...
0 Comments
© 2024 MMIT

Experts Slam Trump’s $200 Medicare Drug Card Proposal

Experts say a last-minute proposal by President Donald Trump to distribute $200 prescription drug credits to Medicare Part D enrollees on preloaded debit cards faces many unanswered questions and will be difficult t...
0 Comments
© 2024 MMIT

News Briefs

✦ Manufacturer prices for insulin in the United States were “considerably” — often five or 10 times — higher than those in other Organisation for Economic Co-operation and Development countries, according ...
0 Comments
© 2024 MMIT

Demos Could Result From ‘Most Favored Nation’ Order

The Trump administration’s long-awaited executive order that seeks to tie U.S. drug prices to costs in other countries may represent more presidential campaign talking points than real policy that will take effect...
0 Comments
© 2024 MMIT

Execs Detail Payers’ Role in COVID-19 Vaccine Distribution

As the pharmaceutical industry hurtles toward completing a COVID-19 vaccine, payers and PBMs have begun to draft vaccine distribution plans based on emerging guidance from federal public health leaders. Insurance in...
0 Comments
© 2024 MMIT

New Process Might Help Make CAR-T Therapies Less Expensive

This summer, a drug called Tecartus (brexucabtagene autoleucel) became the third chimeric antigen receptor T-cell (CAR-T) therapy approved by the FDA. CAR-T therapies, which use a patient’s genetically modified im...
0 Comments
© 2024 MMIT